Beyond Air's NeuroNOS Gains FDA Orphan Drug Status for Glioblastoma Therapy

Beyond Air shares are trading higher after its subsidiary NeuroNOS received FDA Orphan Drug Designation for their investigational glioblastoma treatment, BA-101.